Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019630 · ClinicalTrials.gov registry record · Phase 1
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
A Phase 1 study of Brain Tumor and Bone Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
NCT00019630: Completed Phase 1 study of Brain Tumor and Bone Cancer, sponsored by National Cancer Institute (NCI).
NCT00019630 is a Phase 1 study of Brain Tumor and Bone Cancer that has completed, run by National Cancer Institute (NCI). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019630, a Phase 1 study of Brain Tumor and Bone Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have refractory solid tumors.
Conditions Studied
Interventions
- DRUG doxorubicin HCl liposome
Study Locations (2)
Maryland
- Pediatric Oncology Branch - Bethesda
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Phase | Phase 1 |
What the finished NCT00019630 record still lists
NCT00019630 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 5 conditions, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which doxorubicin HCl liposome is the first listed.
NCT00019630 reports a single indexed study location in Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00019630 about?
NCT00019630 is a clinical study titled "Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have refractory solid tumors.
What is the current status of trial NCT00019630?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-07.
What conditions does trial NCT00019630 study?
This clinical trial studies the following conditions: Brain Tumor, Bone Cancer, Childhood Soft Tissue Sarcoma, Kidney Tumor, Childhood Liver Cancer.
What interventions are being tested in trial NCT00019630?
The interventions under investigation include: doxorubicin HCl liposome (DRUG).
Who is sponsoring clinical trial NCT00019630?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00019630 being conducted?
This trial has 2 study locations across Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia